Our Story

There are around 10,300 new bladder cancer cases in the UK every year (1). Our journey began by being one of them.

About ten years ago, one of the founders of Videometrics went through the bladder cancer patient care pathway and being an expert in image analysis, he immediately recognised that this was an area where our skillsets could help.

Therefore, the team here at Biosignatures partnered with the clinical experts at Newcastle Upon Tyne Hospitals (NUTH) and armed with their strengths and experience in urology and our strengths in visual perception, advanced imaging software plus a strong personal motivation, formed the Videometrics concept. An innovative, new medical device which we believe will revolutionise the management of bladder cancer.

With support from Innovate UK, we ran a study called CICERO (CANC 4362) which gained us direct access to the challenges clinicians face, and well as significant data to support our development of the system.

To keep up to date with the latest innovations check back regularly or email to find out more about our clinical studies: info@bladderimaging.com.

References: 1. Cancer Research UK. Bladder cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer#heading-Zero [Accessed July 2018]

Clinical Study Success

Bringing together clinicians and developers is essential for research and development in health care innovations. We believe that creating a network of ideas, approaches and feedback is an essential part of any new system to guarantee a high level of relevance. This is why our R&D starts in the clinic, talking to the experts. The CICERO study, run in partnership with NUTH and supported by Innovate UK, gained us direct access to the clinicians and highlighted the challenges they face. This ensured important decisions were made accurately in the early stages of Videometrics. In addition, we were able to test the performance of the features and enhancements with real patient data, as we built an archive of cystoscopy examination recordings as part of the project.


This would not have been possible without the support of Innovate UK, the funding allowed us to fund the CICERO study as well as building the project team and successfully developing the system. The support made a huge difference and allowed us to proceed into the development stage accurately and faster than would have otherwise been possible.


Will Dracup, CEO: “The whole process was absolutely key to making sure we were going in the right direction, and I would say the biggest benefit was the interactions with the clinical experts to ensure that the product does what they need.”

To find out more about our clinical studies email: info@bladderimaging.com or visit our studies page for the latest information.

Research and Development Program Update

Videometrics has a program of ongoing research and development to further optimise the diagnosis of bladder cancer and improve patient care. As part of our ongoing efforts we are collecting clinical data to support our innovations. We are now in the process of putting together a multisite study to gather evidence of the economic benefits for Videometrics, to develop our “cystograph” technology and to collect data for an exciting long term AI project. Check back early summer for further updates, but in the meantime, please do get in touch if you’d like to find out more about Videometrics.

Next clinical study plans supported by patient perspectives group

In 2018 Biosignatures plans to initiate a multisite study to evaluate the utility and efficiency of the Videometrics system with the cystograph (bladder mapping) technology. As part of the initial planning for this study, we attended a Perspectives In Cancer Research Group meeting. This is a group of volunteers who all have personal experience of cancer, the group objective is to support cancer research at the Freeman Hospital in Newcastle.

The meeting gave us a valuable insight into the patient perspective of the system and the utility of the bladder mapping technology as a tool to assist in the patient pathway and current procedures.

Biosignatures are looking for hospitals to be involved in the study, if you would like to be involved, or have any questions, please contact Sarah Groves our Clinical Operations Manager:

Email: Sarah.groves@biosignatures.co.uk
Phone: +44 (0) 191 645 3645

Technical development has already started on the creation of a map of the bladder walls, however, no video has yet provided us with full coverage of the bladder. We hope this study can demonstrate the utility of a systematic review of the whole bladder.

The second stage of CICERO study is underway

The CICERO study (Cystoscopic Imaging Collection and Enhancement pROject) had two aims.

  1. Clinically evaluate the use of the software within the clinic
  2. Evaluate the potential clinical benefit of image enhancement.

Phase 1 went very well and we now have a large collection of cystoscopy video clips to demonstrate the enhancement features.

In May 2017 the next stage of the project will begin – a formal review of selected clips to evaluate the potential clinical benefits of the image enhancement. For more information on the image enhancement features click here.